|
|
|
|
|
|
|
|
Journal of Ovarian Research | Full Text
Background
As we have previously
reported, small cell carcinoma of the ovary (SCCO) is a rare, aggressive
form of ovarian cancer associated with poor outcomes. In an effort to
identify new treatment options, we utilized comprehensive genomic
profiling to assess the potential for novel therapies in SCCO.
Conclusion
Neuroendocrine
cancers of the ovary are rare malignancies. With no recurrent
actionable mutations, treatment remains a challenge. Future clinical
trials looking at standard of care chemotherapy using platinum based
chemotherapeutics and comparing that to specific chemotherapy regimens
based off of IHC mutations may prove to be of significance in treating
this rare disease. Our study showed that all SCCO types showed high
expression of TOP2A, therefore, trials comparing platinum based
therapies to topoisomerase II inhibitors such as doxorubicin or
etoposide in patients who have high expression of ERCC1, which is
associated with platinum resistance, may lead to a change in our
approach to this subset of diseases. Also, there is potential for
clinical trials comparing standard chemotherapy to PD1/PDL1 inhibition
in SCCO as our subset of SCCO patients showed increased expression of
PD1 and PDL1. Novel treatment options can be used on a case-by-case
basis depending on the genomic profile. Prospective studies need to be
conducted for better results, but given the rarity of this disease, that
may prove to be difficult.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.